HK1030749A1 - Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors - Google Patents

Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Info

Publication number
HK1030749A1
HK1030749A1 HK01101680A HK01101680A HK1030749A1 HK 1030749 A1 HK1030749 A1 HK 1030749A1 HK 01101680 A HK01101680 A HK 01101680A HK 01101680 A HK01101680 A HK 01101680A HK 1030749 A1 HK1030749 A1 HK 1030749A1
Authority
HK
Hong Kong
Prior art keywords
benzoxazinones
reverse transcriptase
oral liquid
liquid formulations
transcriptase inhibitors
Prior art date
Application number
HK01101680A
Other languages
English (en)
Inventor
Surendra M Bahal
Michael B Maurin
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of HK1030749A1 publication Critical patent/HK1030749A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01101680A 1998-02-17 2001-03-08 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors HK1030749A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7488198P 1998-02-17 1998-02-17
PCT/US1999/003318 WO1999040921A2 (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
HK1030749A1 true HK1030749A1 (en) 2001-05-18

Family

ID=22122226

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101680A HK1030749A1 (en) 1998-02-17 2001-03-08 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Country Status (19)

Country Link
US (1) US6235733B1 (xx)
EP (1) EP1054674B1 (xx)
JP (1) JP2002502878A (xx)
CN (1) CN1170541C (xx)
AR (1) AR018092A1 (xx)
AT (1) ATE345802T1 (xx)
AU (1) AU745008C (xx)
BR (2) BRPI9908132B8 (xx)
CA (1) CA2319609C (xx)
DE (1) DE69934097T2 (xx)
ES (1) ES2277429T3 (xx)
HK (1) HK1030749A1 (xx)
HR (1) HRP990049A2 (xx)
IL (1) IL137763A0 (xx)
MY (1) MY139034A (xx)
NZ (1) NZ506579A (xx)
TW (1) TW528596B (xx)
WO (1) WO1999040921A2 (xx)
ZA (1) ZA99981B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095926T5 (es) * 1990-11-02 2001-02-16 Novartis Ag Cyclosporins.
US5494936A (en) * 1992-04-27 1996-02-27 Vyrex Corporation Delivery formulation for probucol
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (en) 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
CA2252915A1 (en) 1996-05-02 1997-11-06 Merck & Co., Inc. Hiv protease inhibitors useful for the treatment of aids
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same

Also Published As

Publication number Publication date
BRPI9908132B1 (pt) 2015-07-14
BRPI9908132B8 (pt) 2016-11-16
AU2682799A (en) 1999-08-30
CN1291098A (zh) 2001-04-11
TW528596B (en) 2003-04-21
AR018092A1 (es) 2001-10-31
CA2319609C (en) 2007-09-18
DE69934097D1 (de) 2007-01-04
CN1170541C (zh) 2004-10-13
ZA99981B (en) 2000-08-08
BRPI9908132C1 (pt) 2021-05-25
CA2319609A1 (en) 1999-08-19
BR9908132A (pt) 2000-12-05
ATE345802T1 (de) 2006-12-15
AU745008B2 (en) 2002-03-07
ES2277429T3 (es) 2007-07-01
WO1999040921A3 (en) 1999-11-04
HRP990049A2 (en) 1999-12-31
EP1054674A2 (en) 2000-11-29
MY139034A (en) 2009-08-28
JP2002502878A (ja) 2002-01-29
WO1999040921A2 (en) 1999-08-19
DE69934097T2 (de) 2007-06-28
NZ506579A (en) 2002-11-26
EP1054674B1 (en) 2006-11-22
AU745008C (en) 2003-03-27
IL137763A0 (en) 2001-10-31
US6235733B1 (en) 2001-05-22

Similar Documents

Publication Publication Date Title
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
AU1694295A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
HUP0103217A2 (hu) Orális folyékony mukoadhezív készítmények és alkalmazásuk
EP1196147A4 (en) BUILDING COMPOSITIONS
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
HUP0202593A3 (en) Benzophenones as inhibitors of reverse transcriptase
IL156354A0 (en) Pyridoindole derivatives and pharmaceutical compositions containing the same
HK1061037A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
HUP0104379A3 (en) New crystalline form of omeprazole and medicament containing it
ATE231393T1 (de) Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend
AU3461299A (en) Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
IL141234A0 (en) Combination of two or more active ingredients using microencapsulated formulations
HUP0202495A3 (en) Stable medicinal compositions for oral use
HU9901570D0 (en) Use of nanodispersions in pharmaceutical compositions
EP1109532A4 (en) ORAL COMPOSITION AS A MICROEMULSION OF SILYBINE
EP1322332A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 INFECTION
IL152094A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
ID27728A (id) Komposisi-komposisi mukoadesif oral yang mengandung bahan-bahan aktif gastrointestinal
IL156577A0 (en) Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
PT1014987E (pt) Composicoes orais de levosimendano
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
IL162325A0 (en) Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
EP1086091A4 (en) HIV INTEGRASE INHIBITORS
EP1050583A4 (en) INHIBITORS OF HIV INFECTIONS
DE69807768D1 (de) Rapamycin enthaltende Formulierungen zur oralen Verabreichung

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: BRISTOL-MYERS SQUIBB PHARMA COMPANY

Free format text: FORMER OWNER(S): DU PONT PHARMACEUTICALS COMPANY

PE Patent expired

Effective date: 20190216